I've always liked NVO and probably feel it could be priced right at these levels. What's holding me back is that I feel there will be certain pharma sectors who'll have to correct their pricing models. As an individual drug Humira would have to be number #1, and then closely followed the Diabetes, MS and Cancer groups. The model is nothing besides silly.